SEC 13F Intelligence

Managers / Q3 2023 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$111M
Q3 2023
Positions
43
Filings on Record
24
2019–present window
Filed
Nov 14, 2023
original filing

Summary

Endurant Capital Management LP reported $111M in U.S.-listed holdings across 43 positions for Q3 2023.

Its largest position, BMRN, represents 14.3% of the portfolio.

Compared with Q2 2023, the fund opened 25 new positions and exited 15.

Portfolio Metrics

Turnover
+65.0%
vs prior filed quarter
Top-10 Concentration
+57.5%
share of reported value
Largest Position
+14.3%
Biomarin Pharmaceutical
New / Exited
25 / 15
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 80.7%ADR: 10.1%REIT: 4.9%Other: 4.0%ETP: 0.3%
  • Common Stock · 80.7% · $90M
  • ADR · 10.1% · $11M
  • REIT · 4.9% · $5M
  • Other · 4.0% · $4M
  • ETP · 0.3% · $301,546

Quarter-over-Quarter Changes full breakdown →

vs Q2 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TMOTHERMO FISHER SCIENTIFIC INCNEW+13.8K13.8K+$7M$7M
AVTRAVANTOR INCNEW+226.9K226.9K+$5M$5M
CNMDCONMED CORPNEW+42.0K42.0K+$4M$4M
COOPER COS INCNEW+11.5K11.5K+$4M$4M
HUMHUMANA INCNEW+6.6K6.6K+$3M$3M
TXG10X GENOMICS INCNEW+71.0K71.0K+$3M$3M
SBCSABRA HEALTH CARE REIT INCNEW+203.8K203.8K+$3M$3M
OMEGA HEALTHCARE INVS INCNEW+80.1K80.1K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2023

43 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMRNBIOMARIN PHARMACEUTICAL INChistory →COM14.27%$16M179.6K
2TMOTHERMO FISHER SCIENTIFIC INChistory →COM6.30%$7M13.8K
3BRKRBRUKER CORPhistory →COM6.23%$7M111.3K
4AZNNASTRAZENECA PLChistory →SPONSORED ADR5.87%$7M96.4K
5ELVELEVANCE HEALTH INChistory →COM5.28%$6M13.5K
6AVTRAVANTOR INChistory →COM4.30%$5M226.9K
7MRKMERCK & CO INChistory →COM4.10%$5M44.4K
8ARGXARGENX SEhistory →SPONSORED ADR4.02%$4M9.1K
9CNMDCONMED CORPhistory →COM3.80%$4M42.0K
10COOPER COS INCCOM NEW3.29%$4M11.5K
11HUMHUMANA INChistory →COM2.88%$3M6.6K
12TXG10X GENOMICS INChistory →CL A COM2.63%$3M71.0K
13SBCSABRA HEALTH CARE REIT INChistory →COM2.55%$3M203.8K
14OMEGA HEALTHCARE INVS INCCOM2.38%$3M80.1K
15BSXBOSTON SCIENTIFIC CORPhistory →COM2.27%$3M47.9K
16KIDSORTHOPEDIATRICS CORPhistory →COM2.02%$2M70.4K
17ABGCENCORA INChistory →COM1.88%$2M11.6K
18SYKSTRYKER CORPORATIONhistory →COM1.85%$2M7.5K
19IM8NINSMED INChistory →COM PAR $.011.80%$2M79.5K
20ZBHZIMMER BIOMET HOLDINGS INChistory →COM1.76%$2M17.5K
21QDELQUIDELORTHO CORPhistory →COM1.75%$2M26.7K
22DC4DEXCOM INChistory →COM1.73%$2M20.7K
23THCTENET HEALTHCARE CORPhistory →COM NEW1.61%$2M27.2K
24ABTABBOTT LABShistory →COM1.57%$2M18.0K
25CITHE CIGNA GROUPhistory →COM1.56%$2M6.1K
26PODDINSULET CORPhistory →COM1.27%$1M8.9K
27ETNBGBP89BIO INChistory →COM1.14%$1M82.2K
28HO1HOLOGIC INChistory →COM1.11%$1M17.8K
29OCULOCULAR THERAPEUTIX INCCOM1.00%$1M353.7K
30AZTAAZENTA INCCOM0.88%$974,79019.4K
31TARSTARSUS PHARMACEUTICALS INCCOM0.76%$846,72347.6K
32AHCOADAPTHEALTH CORPCOMMON STOCK0.74%$818,42789.9K
33AXSMAXSOME THERAPEUTICS INCCOM0.71%$786,54211.3K
34IQVIQVIA HLDGS INCCOM0.70%$776,3763.9K
35BLUEBIRD BIO INCCOM0.69%$765,426251.8K
36OLMAOLEMA PHARMACEUTICALS INCCOM0.65%$723,37758.6K
37VTYXUSDVENTYX BIOSCIENCES INCCOM0.58%$641,04618.5K
38ACLXGBXARCELLX INCCOMMON STOCK0.46%$507,98914.2K
39GDRXGOODRX HLDGS INCCOM CL A0.44%$491,44387.3K
40SELECTA BIOSCIENCES INCCOM0.43%$480,513453.3K
41ISHARES TR20 YR TR BD ETF0.27%$301,5463.4K
42NVSTENVISTA HOLDINGS CORPORATIONCOM0.27%$300,74210.8K
43ADAPYADAPTIMMUNE THERAPEUTICS PLCSPONDS ADR0.22%$243,316311.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.